Darunavir · Prezista

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HIV

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
EU
  • HIV-1 infection with low-dose ritonavir and other HIV medicines, patients from 3 years of age weighing at least 15 kg (Prezista)
Product first approved 2007EMA
CA
  • HIV-1 infection in treatment-experienced adults, with ritonavir (Prezista; Notice of Compliance with Conditions)
Product first approved 2006dhpp.hpfb-dgpsa.ca

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (34)
HIV
NCT07792096 · University College, London
2026-11 – 2029-12 · HIV Infection
What this study did
NCT03988452 · Makerere University
2019-07-30 – 2021-09-30 · Human Immunodeficiency Virus
What this study did
NCT01792570 · ASST Fatebenefratelli Sacco
2014-09-30 – 2018-12-31 · Human Immunodeficiency Virus
What this study did
NCT02486133 · Technical University of Munich
2015-07 – 2018-05-31 · HIV-Infection
What this study did
NCT02671383 · Willem Daniel Francois Venter
2016-06-30 – 2018-05-16 · HIV Infections
What this study did
NCT00855335 · Janssen Scientific Affairs, LLC
2009-04-09 – 2016-08-11 · HIV, HIV Infections, Pregnancy
What this study did
NCT02155101 · University of Liverpool
2014-05 – 2016-07 · HIV/AIDS
What this study did
NCT00928187 · ANRS, Emerging Infectious Diseases
2009-11 – 2015-12 · HIV, HIV Infections
What this study did
NCT01440569 · Gilead Sciences
2011-09 – 2015-10 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
NCT01448707 · Janssen-Cilag International NV
2012-03-15 – 2015-03-18 · Human Immunodeficiency Virus (HIV) Infections, Acquired Immunodeficiency Syndrome (AIDS) Virus
What this study did
NCT01363011 · Gilead Sciences
2011-05 – 2015-02 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
NCT01605084 · Bristol-Myers Squibb
2012-06-30 – 2014-08-31 · HIV
What this study did
NCT01033760 · ANRS, Emerging Infectious Diseases
2010-04 – 2013-12 · HIV-1 Infections
What this study did
NCT01066962 · ANRS, Emerging Infectious Diseases
2010-08 – 2013-10 · HIV Infections
What this study did
NCT01516970 · Janssen-Cilag G.m.b.H
2011-11-25 – 2013-09-28 · Human Immunodeficiency Virus (HIV)
What this study did
NCT00811954 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2009-05 – 2013-06 · HIV Infection
What this study did
NCT00537394 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-01 – 2013-04 · HIV Infections
What this study did
NCT00524368 · Tibotec Pharmaceuticals, Ireland
2007-10 – 2011-10 · Human Immunodeficiency Virus - Type 1
What this study did
NCT00849160 · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
2009-05 – 2011-09 · HIV-1 Infection, HIV Infections
What this study did
NCT00421551 · French National Agency for Research on AIDS and Viral Hepatitis
2007-03 – 2011-02 · HIV Infections
What this study did
NCT00458302 · Janssen-Cilag International NV
2007-06 – 2011-01 · HIV Infections, AIDS Virus, Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome Virus
What this study did
NCT00517192 · Boehringer Ingelheim
2007-09 – 2008-09 · HIV Infections
What this study did
Other / comorbidity
NCT04252274 · Shanghai Public Health Clinical Center
2020-01-30 – 2020-12-31 · Pneumonia, Pneumocystis, Coronavirus
What this study did
Phase 2/3 (3)
HIV
NCT02016924 · Gilead Sciences
2014-01-16 – 2027-03 · Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
What this study did
NCT02383108 · PENTA Foundation
2016-06 – 2020-10 · HIV Infection
What this study did
NCT02499978 · Stanford University
2016-05 – 2016-06 · HIV/AIDS
What this study did
Phase 2 (24)
HIV
NCT03602690 · ANRS, Emerging Infectious Diseases
2018-10-04 – 2022-04-11 · HIV/AIDS
What this study did
NCT02738502 · ANRS, Emerging Infectious Diseases
2016-07-06 – 2020-07-16 · Maternal-fetal Infection Transmission
What this study did
NCT03589027 · Makerere University
2018-08-07 – 2020-06 · HIV-1-infection, Contraception
What this study did
NCT03589040 · Makerere University
2018-09-25 – 2020-06 · HIV, Contraception
What this study did
NCT02025868 · ANRS, Emerging Infectious Diseases
2013-03 – 2017-05 · HIV Infection
What this study did
NCT02384967 · ANRS, Emerging Infectious Diseases
2015-03 – 2016-10 · HIV INFECTION
What this study did
NCT01400412 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2012-01-17 – 2014-06-30 · HIV-1 Infection
What this study did
NCT00993148 · Northwestern University
2010-05 – 2013-04 · HIV-1 Infection, HIV Infections
What this study did
NCT01199939 · Tibotec, Inc
2010-05 – 2012-10 · Human Immunodeficiency Virus (HIV)
What this study did
NCT00355524 · Tibotec Pharmaceuticals, Ireland
2006-06 – 2011-03 · HIV-1, HIV Infections
What this study did
NCT00915655 · Tibotec Pharmaceuticals, Ireland
2009-07 – 2011-03 · HIV-1 Infection
What this study did
NCT00919854 · Tibotec Pharmaceuticals, Ireland
2009-09 – 2011-02 · Human Immunodeficiency Virus 1
What this study did
NCT00830804 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2009-04 – 2010-09 · HIV-1 Infections
What this study did
NCT00460382 · French National Agency for Research on AIDS and Viral Hepatitis
2007-05 – 2009-09 · HIV Infections
What this study did
NCT02187107 · Tibotec Pharmaceuticals, Ireland
2005-01 – 2009-03 · HIV
What this study did
NCT00081588 · Tibotec Pharmaceuticals, Ireland
2003-11 – 2008-12 · HIV Infection
What this study did
NCT00071097 · Tibotec Pharmaceuticals, Ireland
2003-10 – 2007-11 · HIV Infections
What this study did
Phase 1/2 (5)
HIV
NCT06139796 · PENTA Foundation
2025-02-01 – 2025-07-09 · HIV Infections
What this study did
NCT02475915 · SEARCH Research Foundation
2015-01 – 2016-03 · Acute HIV Infection
What this study did
NCT00885495 · University of Cincinnati
2009-01 – 2010-08 · HIV Infections
What this study did
NCT00260078 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-02 – 2009-04 · HIV Infections
What this study did
Phase 1 (48)
HIV
NCT05197075 · Janssen Research & Development, LLC
2022-08-03 – 2022-09-23 · Human Immunodeficiency Virus (HIV)
What this study did
NCT04630002 · ViiV Healthcare
2020-10-28 – 2021-10-02 · HIV Infections
What this study did
NCT02771249 · National Institutes of Health Clinical Center (CC)
2016-06-03 – 2021-08-17 · HIV Infected Population With Latent Tuberculosis
What this study did
NCT03472963 · Emory University
2018-04-27 – 2019-03-29 · HIV Infections
What this study did
NCT03892161 · University of Cape Town
2018-04-12 – 2018-11-22 · HIV Infections
What this study did
NCT03094507 · St Stephens Aids Trust
2017-04-19 – 2018-03-17 · HIV
What this study did
NCT02818348 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2016-06 – 2016-11-23 · HIV-1 Infection
What this study did
NCT02589158 · St Stephens Aids Trust
2015-11 – 2016-03 · HIV
What this study did
NCT02277600 · ViiV Healthcare
2014-11-05 – 2015-01-12 · Infection, Human Immunodeficiency Virus
What this study did
NCT02489487 · Viriom
2014-09 – 2014-10 · HIV-infection
What this study did
NCT02063360 · ViiV Healthcare
2014-02-01 – 2014-05-13 · Infection, Human Immunodeficiency Virus
What this study did
NCT01695954 · NYU Langone Health
2012-05 – 2013-01 · Hyperlipidemia, HIV
What this study did
NCT01348763 · Imperial College London
2011-10 – 2012-05 · HIV
What this study did
NCT01374802 · Boehringer Ingelheim
2011-06 – 2011-07 · HIV Infections
What this study did
NCT01876966 · Janssen Pharmaceutica N.V., Belgium
2011-03 – 2011-07 · HIV
What this study did
NCT00936793 · National Institutes of Health Clinical Center (CC)
2009-07-06 – 2011-06-10 · HIV, Asthma
What this study did
NCT00855088 · University of North Carolina, Chapel Hill
2009-07 – 2011-02 · HIV/AIDS, HIV Infections
What this study did
NCT01073761 · St Stephens Aids Trust
2010-04 – 2010-06 · HIV, HIV Infections
What this study did
NCT00307502 · Germans Trias i Pujol Hospital
2005-01 – 2009-12 · HIV Infections
What this study did
NCT01047995 · St Stephens Aids Trust
2009-06 – 2009-12 · HIV Infections
What this study did
NCT00920088 · GlaxoSmithKline
2009-06 – 2009-11 · Healthy Subjects, Infection, Human Immunodeficiency Virus
What this study did
NCT00744887 · Tibotec Pharmaceuticals, Ireland
2008-08 – 2008-12 · HIV, AIDS
What this study did
NCT00765271 · St Stephens Aids Trust
2008-05 – 2008-10 · HIV
What this study did
Other / comorbidity
NCT02437110 · National Institute of Neurological Disorders and Stroke (NINDS)
2019-04-01 – 2023-05-09 · Amyotrophic Lateral Sclerosis
What this study did
NCT03864406 · National Institutes of Health Clinical Center (CC)
2019-06-04 – 2022-12-10 · Healthy Volunteers
What this study did
NCT04208061 · Janssen Research & Development, LLC
2019-12-18 – 2021-04-01 · Healthy
What this study did
NCT04718805 · Janssen Research & Development, LLC
2021-01-26 – 2021-03-01 · Healthy
What this study did
NCT02625207 · ViiV Healthcare
2015-11-06 – 2016-03-26 · Healthy Subjects
What this study did
NCT02578550 · Janssen Sciences Ireland UC
2015-11 – 2016-02 · Healthy
What this study did
NCT02475135 · Janssen Sciences Ireland UC
2015-06-01 – 2015-08-14 · Healthy
What this study did
NCT02203461 · Technical University of Munich
2014-07 – 2014-10 · Insulin Resistance
What this study did
NCT02159352 · Bristol-Myers Squibb
2014-06 – 2014-07 · Hepatitis C
What this study did
NCT01619527 · Janssen R&D Ireland
2012-04 – 2012-08 · Healthy Participants
What this study did
NCT01519336 · Hoffmann-La Roche
2012-02 – 2012-03 · Healthy Volunteer
What this study did
NCT00783484 · Pfizer
2008-10 – 2009-05 · Healthy Volunteers
What this study did
NCT00867152 · ViiV Healthcare
2009-04 – 2009-05 · Healthy Volunteer
What this study did
NCT00752310 · Tibotec Pharmaceuticals, Ireland
2008-04 – 2008-08 · Pharmacokinetics
What this study did
Phase 4 (48)
HIV
NCT06337032 · Gilead Sciences
2024-08-27 – 2034-03 · HIV-1-infection
What this study did
NCT07678268 · Instituto Mexicano del Seguro Social
2025-07-10 – 2026-12-10 · HIV Infection, Antiretroviral Therapy, Lentivirus Infections
What this study did
NCT05463783 · East Carolina University
2023-03-14 – 2025-03 · HIV Infections, Obesity
What this study did
NCT04388904 · The Crofoot Research Center, Inc.
2021-09-01 – 2024-04-05 · HIV-1-infection
What this study did
NCT03675815 · Kirby Institute
2019-12-05 – 2024-01-15 · HIV Infections
What this study did
NCT03017872 · Kirby Institute
2017-11-23 – 2023-10-31 · HIV Infections
What this study did
NCT04183738 · Kirby Institute
2021-02-01 – 2022-12-19 · HIV-infection/Aids, Human Herpesvirus 4 Infections, Cytomegalovirus Infections, Human Herpesvirus 8 Infection, Human Papilloma Virus
What this study did
NCT03683524 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2018-11-19 – 2021-08-10 · HIV-1 Infection
What this study did
NCT03447873 · Hospitales Universitarios Virgen del Rocío
2017-06-01 – 2021-02-03 · HIV Infections
What this study did
NCT03163277 · Giovanni Di Perri
2017-05-15 – 2020-06-30 · Hiv, Neurocognitive Dysfunction
What this study did
NCT02337322 · Juan A. Arnaiz
2015-03-31 – 2019-12 · Acquired Immune Deficiency Syndrome Virus
What this study did
NCT04064632 · A.O. Ospedale Papa Giovanni XXIII
2017-02-01 – 2019-11-30 · HIV Infection
What this study did
NCT03101644 · Université Catholique de Louvain
2017-03-23 – 2019-06-12 · Human Immunodeficiency Virus I Infection
What this study did
NCT01641367 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2013-02-22 – 2018-12-31 · HIV-1 Infection
What this study did
NCT02770508 · Fundación Huésped
2015-11 – 2017-10 · HIV-1 Infection
What this study did
NCT02199613 · University of British Columbia
2014-10 – 2017-02-14 · HIV Infection
What this study did
NCT02503462 · University Hospital, Basel, Switzerland
2015-07 – 2017-01 · AIDS-related Dementia Complex
What this study did
NCT01869634 · University of California, Davis
2013-06 – 2016-12 · Human Immunodeficiency Virus Infection
What this study did
NCT02404233 · Therapeutic Concepts
2015-03 – 2016-12 · HIV Positive
What this study did
NCT01367236 · Imperial College London
2013-01 – 2015-10 · HIV, Impaired Cognition
What this study did
NCT01367210 · Catholic University of the Sacred Heart
2011-06 – 2015-06 · HIV Infection
What this study did
NCT01423812 · Ruth M. Rothstein CORE Center
2012-01 – 2015-04 · HIV
What this study did
NCT01258439 · St Vincent's Hospital, Sydney
2010-11 – 2014-07 · HIV, Cardiovascular Disease
What this study did
NCT00855413 · University of North Carolina, Chapel Hill
2009-03 – 2013-11 · Acute HIV Infection, HIV Infections
What this study did
NCT01118871 · Imperial College London
2010-05 – 2013-05 · HIV, HIV Infections
What this study did
NCT01928407 · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
2011-02-23 – 2013-01-07 · HIV-1 Infection, Immunosuppression-related Infectious Disease
What this study did
NCT00677300 · Dallas VA Medical Center
2009-01 – 2012-12 · HIV Infections
What this study did
NCT01346982 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2011-03 – 2011-07 · HIV
What this study did
NCT00756730 · Community Research Initiative of New England
2008-09 – 2011-06 · HIV Infections
What this study did
NCT00630734 · University of Colorado, Denver
2008-02 – 2010-09 · HIV Infections, Hyperlipidemia
What this study did
NCT00765154 · St Stephens Aids Trust
2008-10 – 2010-07 · HIV
What this study did
NCT01046890 · Germans Trias i Pujol Hospital
2010-01 – 2010-04 · HIV Infections
What this study did
NCT01013987 · Fundación Huésped
started 2010-02 · HIV-1 Adults Patients, AIDS, Triple Class Failure
What this study did
NCT00543101 · Community Research Initiative of New England
2007-10 – 2010-02 · HIV Infections
What this study did
NCT00611039 · Germans Trias i Pujol Hospital
2008-02 – 2009-07 · HIV Infections
What this study did
NCT00531557 · St Stephens Aids Trust
2007-09 – 2008-11 · HIV Infections
What this study did
Other / comorbidity
NCT01422369 · Kowa Research Institute, Inc.
2011-04 – 2011-06 · Healthy
What this study did
NCT01810887 · Janssen Pharmaceutical K.K.
2008-05 – 2008-07 · Healthy
What this study did
Early phase / not applicable (4)
HIV
NCT02097381 · University of Roma La Sapienza
2010-04 – 2014-12 · HIV Infection
What this study did
NCT00525733 · Rockefeller University
2007-10 – 2013-12 · HIV Infections
What this study did
NCT01294761 · National Center for Global Health and Medicine, Japan
2011-02 – 2013-12 · HIV Infections
What this study did
Other / comorbidity
NCT04268472 · Geropharm
2019-06-06 – 2019-09-06 · Bioequivalence
What this study did
Used as active comparator (12)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
HIV
NCT06747507 · University of Nairobi
2025-09-01 – 2027-07 · HIV-1-infection
What this study did
NCT02275780 · Merck Sharp & Dohme LLC
2014-12-01 – 2023-03-06 · HIV-1
What this study did
NCT02987530 · ANRS, Emerging Infectious Diseases
2017-04-11 – 2020-01-31 · HIV-1 Infection
What this study did
NCT01900106 · University of Modena and Reggio Emilia
2013-11 – 2017-12 · HIV Infection
What this study did
NCT01449929 · ViiV Healthcare
2011-10-31 – 2016-12-26 · Infection, Human Immunodeficiency Virus
What this study did
Phase 2 (2)
Phase 1 (1)
Other / comorbidity
Phase 4 (3)
HIV
NCT06787976 · Instituto Mexicano del Seguro Social
2025-06-19 – 2026-01-25 · HIV, Insomnia, Anxiety
What this study did
NCT03842488 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
2019-04 – 2021-03 · HIV Infections
What this study did
NCT02470650 · Juan A. Arnaiz
2015-06 – 2017-10 · Patient Compliance, Antiretroviral Therapy Intolerance
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
HIV
NCT06338826 · ANRS, Emerging Infectious Diseases
2025-02-01 – 2027-09-30 · HIV Infections, HBV Coinfection
What this study did
Phase 1 (1)
HIV
NCT00877591 · University of California, San Francisco
2008-04 – 2013-04 · Opioid Dependency, HIV Infections
What this study did
Early phase / not applicable (1)
HIV
NCT03394196 · University of Washington
2018-07-04 – 2020-05-31 · HIV-2 Infection
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for HIV: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Darunavir (Prezista): this drugApprovedSmall moleculeHIV proteasePartial signal
NCT00110877: HIV RNA <400 copies/mL at Week 48 (per-protocol population): darunavir-ritonavir 77% (220/286) vs lopinavir-ritonavir 68% (199/293); estimated difference 9% (95% CI 2-16).
Amprenavir
ApprovedUS marketing discontinued
Small moleculeHIV proteasenot yet gradedNo reviewed efficacy summary in this indication
Bictegravir (Biktarvy)ApprovedSmall moleculeHIV integraseReliable signal
NCT03110380: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis).
NCT02607956: Week 48 HIV-1 RNA <50 copies/mL: 89.4% B/F/TAF vs 92.9% DTG + F/TAF; difference -3.5 percentage points (95.002% CI -7.9 to 1.0); prespecified non-inferiority margin 12%.
Bictegravir / Lenacapavir (Bixlenvo)ApprovedSmall moleculeHIV integrase, HIV capsidPartial signal
NCT05502341: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results).
Cabotegravir (Apretude)ApprovedSmall moleculeHIV integraseReliable signal
NCT02720094: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281
Cabotegravir / Rilpivirine (Cabenuva)ApprovedSmall moleculeHIV integrase, HIV reverse transcriptaseWeak signal
NCT03299049: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results).
NCT02938520: Virologic failure (HIV-1 RNA >=50 copies/mL, FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 4 weeks vs abacavir/dolutegravir/lamivudine: 2.1% vs 2.5%, adjusted difference -0.4% (95% CI -2.8 to 2.1); non-inferior against the 6% margin (CT.gov posted results).
Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component))ApprovedSmall moleculeHIV integraseReliable signal
NCT01263015: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003).
NCT01449929: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 (Week 48): DTG 50 mg QD 90% vs DRV 800 mg + RTV 100 mg QD 83%
Doravirine (Pifeltro)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02403674: Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033).
NCT02275780: Week 48 HIV-1 RNA <50 copies/mL: 83.8% doravirine vs 79.9% darunavir/ritonavir; treatment difference 3.913 percentage points (95% CI -1.590 to 9.415), non-inferiority margin -10 percentage points.
Doravirine / Islatravir (Idvynso)ApprovedSmall moleculeHIV reverse transcriptase, HIV-1 Reverse TranscriptasePartial signal
NCT05630755: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results).
NCT04233879: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3%
Elvitegravir (Stribild)ApprovedSmall moleculeHIV integrasePartial signal
NCT01095796: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1%
Emtricitabine (Emtriva)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00112047: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00323544: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm.
Etravirine (Intelence)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00254046: Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005
NCT00255099: Confirmed viral load <50 copies/mL at Week 24 (intention to treat): etravirine (TMC125) 62% (183/295) vs placebo 44% (129/296); difference 18% (95% CI 11-26; p=0.0003).
Fostemsavir (Rukobia)ApprovedSmall moleculeHIV gp120Partial signal
NCT02362503: Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Randomized Cohort-fostemsavir 600 mg BID -0.791 Log10 copies per milliliter (c/mL) (95% CI -0.885 to -0.698) vs Randomized Cohort-Placebo -0.166 Log10 copies per milliliter (c/mL) (95% CI -0.326 to -0.007)
NCT01384734: HIV-1 RNA < 50 copies/mL at Week 24: fostemsavir 400 mg BID 80% (95% CI 66.3 to 90), 800 mg BID 69% (54.6 to 81.7), 600 mg QD 76% (62.5 to 87.2) and 1200 mg QD 72% (57.5 to 83.8) vs the atazanavir/ritonavir reference arm 75% (60.4 to 85.7).
Ibalizumab (Trogarzo)ApprovedMonoclonal antibodyCD4 receptorWeak signal
NCT02475629: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14): Open-Label Ibalizumab Plus OBR 82.5% (95% CI 67.72% to 92.66%)
Lenacapavir (Sunlenca)ApprovedSmall moleculeHIV capsidPartial signal
NCT04150068: Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants
NCT04143594: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm (Week 54): Group 1: SC LEN+(F/TAF→ TAF) 90.4% vs Group 2: SC LEN + (F/TAF → BIC) 84.9% vs Group 3: Oral LEN + F/TAF 84.6% vs Group 4: B/F/TAF 92.0%; p=0.7178 (Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF), p=0.3900 (Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF), p=0.3797 (Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF) missed
Lenacapavir (Yeztugo)ApprovedSmall moleculeHIV capsidReliable signal
NCT04925752: HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025).
NCT04994509: HIV incidence: 0 infections in 2,134 on twice-yearly lenacapavir (0 per 100 PY; 95% CI 0.00-0.19) vs background incidence 2.41 per 100 PY (IRR 0.00; 95% CI 0.00-0.04; P<0.001) and vs F/TDF 1.69 per 100 PY (IRR 0.00; 95% CI 0.00-0.10; P<0.001) (PURPOSE 1, NEJM 2024).
Maraviroc (Selzentry / Celsentri)ApprovedSmall moleculeCCR5 co-receptorPartial signal
NCT00098293: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population (Week 48): Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) — Less than 400 copies/mL: 61.5%; Less than 50 copies/mL: 55.8% | Maraviroc Twice Daily + CBV (DB) — Less than 400 copies/mL: 70.6%; Less than 50 copies/mL: 65.3% vs Efavirenz Once Daily + CBV (DB) — Less than 400 copies/mL: 73.1%; Less than 50 copies/mL: 69.3%
Raltegravir (Isentress)ApprovedSmall moleculeHIV integraseReliable signal
NCT00293254: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3)
NCT00293267: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.7% (95% CI 71.8 to 82.9) vs Placebo + OBT 41% (95% CI 32 to 50.5)
Rilpivirine (Edurant)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00540449: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%.
NCT00543725: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 (Week 48): TMC278 — Responder: 291/340; Virologic failure: 24/340; Death: 1/340; Discontinued due to AE: 8/340; Discontinued due to other reason than AE: 16/340 vs Efavirenz — Responder: 276/338; Virologic failure: 18/338; Death: 3/338; Discontinued due to AE: 21/338; Discontinued due to other reason than AE: 20/338
Somatropin (Serostim)ApprovedProtein / enzyme therapeuticGrowth hormone receptorPartial signal
NCT00082628: Change in visceral adipose tissue area at Week 12: -32.6 cm² Serostim (n=210) vs 0.5 cm² placebo (n=74), p<0.001. phase 3 result · pivotal pending
NCT01077960: Primary endpoint: mean change in trunk fat from baseline to week 12, -1.7 kg (SD 1.4; n=106; p<0.001). phase 3 result · pivotal pending
Tenofovir Alafenamide / Emtricitabine (Descovy)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02842086: Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564)
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Partial signal
NCT00528957: Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 (48 weeks): Tenofovir DF 83.3 percentage of participants | Stavudine or Zidovudine 91.8 percentage of participants | All TDF 85.4 percentage of participants missed
NCT00352053: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA (Baseline to 24 Weeks): Tenofovir DF -1.58 log10 copies/mL (IQR -2.15 to -0.27) | Placebo -1.549 log10 copies/mL (IQR -2.36 to -0.34) missed
Tesamorelin (Egrifta WR)ApprovedPeptideGrowth hormone-releasing hormone (GHRH) receptorPartial signal
NCT00608023: Changes From Baseline in Fasting Blood Glucose at Week 52 (Baseline and Week 52): Tesamorelin 52 Weeks 0 mg/dL (Standard Deviation 16) missed
Tipranavir (Aptivus)ApprovedSmall moleculeHIV proteasePartial signal
NCT00144170: Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15%
NCT00054717: Treatment Response at Week 48 (At week 48): Tipranavir(TPV)/Low Dose Ritonavir(r) 33.8% vs Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r) 16.2%
ACC017Phase 3Small moleculeHIV integrasePartial signal
NCT06719310: The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29.
Albuvirtide (Aikening)Phase 3PeptideHIV gp41Partial signal
NCT02369965: Primary, HIV-1 RNA <50 copies/mL at week 48 (mITT, interim analysis with 46 albuvirtide and 50 control patients at week 48): 80.4% (37/46) albuvirtide + lopinavir/ritonavir vs 66.0% (33/50) NRTIs + lopinavir/ritonavir; difference 14.4% (95% CI -3.0% to 31.9%) against a prespecified non-inferiority margin of -12%, met.
AlimatravirPhase 3Small moleculeHIV-1 Reverse TranscriptaseWeak signal
NCT06045507: Primary outcomes, safety (no formal efficacy test): participants with at least one adverse event 62/101 (3 mg), 69/101 (6 mg) and 66/99 (12 mg) monthly MK-8527 vs 31 on placebo; discontinuation due to an adverse event 0, 2 and 1 vs 2 (CT.gov posted results).
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasePartial signal
NCT04109183: 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05)
Dapivirine (Dapivirine Vaginal Ring)Phase 3Small moleculeHIV reverse transcriptaseReliable signal
NCT01617096: HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007).
IslatravirPhase 3Small moleculeHIV-1 Reverse Transcriptasenot yet gradedNo reviewed efficacy summary in this indication
Islatravir / LenacapavirPhase 3Small moleculeHIV-1 Reverse Transcriptase, HIV capsidnot yet gradedNo reviewed efficacy summary in this indication
SemzuvolimabPhase 3Monoclonal antibodyCD4 receptorWeak signalNo reviewed efficacy summary in this indication
TeropavimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
ZinlirvimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
Elsulfavirine (Elpida)Phase 2/3Small moleculeHIV reverse transcriptasePartial signalNo reviewed efficacy summary in this indication
LeronlimabPhase 2/3Monoclonal antibodyCCR5 co-receptorWeak signal
NCT02483078: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): PRO 140 — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 64%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 36% | Placebo — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 23%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 77%
NCT02859961: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure (From T1 (first treatment administration) to week 48 (T48).): Part 1 - 350 mg Weekly Injections of PRO 140, Group A 23% | Part 1 - 525 mg Weekly Injections of PRO 140, Group B 43% | Part 1 - 700 mg Weekly Injections of PRO 140, Group C 45%
UlonivirinePhase 2/3Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
10-1074Phase 2Monoclonal antibodyHIV envelopeWeak signalFeatured results are safety only in this race
3BNC117Phase 2Monoclonal antibodyHIV envelopePartial signal
NCT03041012: Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed.
CL-197Phase 2Small moleculeHIV reverse transcriptaseWeak signalNo reviewed efficacy summary in this indication
DezecapavirPhase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969)
EnvafolimabPhase 2Monoclonal antibodyPD-L1Weak signalNo reviewed efficacy summary in this indication
HTI Vaccine (ChAdOx1.HTI / MVA.HTI)Phase 2VaccineHIV-1 conserved epitopes (HTI)Partial signal
NCT03204617: Primary, safety (grade 3 or 4 local and systemic reactions; no formal efficacy test): adverse events were mostly mild and transient, with no related serious adverse events. Secondary: HTI vaccines induced strong, broad CD4 and CD8 T-cell responses; all participants had detectable viral rebound during treatment interruption.
LipovirtidePhase 2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
LotivibartPhase 2Monoclonal antibodyHIV envelopeWeak signal
NCT04871113: Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69)
TMB-365 / TMB-380Phase 2CombinationCD4; HIV envelopenot yet gradedNo reviewed efficacy summary in this indication
TrosunilimabPhase 2Monoclonal antibodyα4β7 integrinPartial signalFeatured results are safety only in this race
VesatolimodPhase 2Small moleculeToll-like receptor 7 (TLR7) (agonist)Weak signalFeatured results are safety only in this race
VH4004280 (VH-280)Phase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574)
VH4524184Phase 2Small moleculeHIV integrasePartial signal
NCT06214052: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37)
JL18008Phase 1/2Protein / enzyme therapeuticIL-7 receptorWeak signalNo reviewed efficacy summary in this indication
LP-98Phase 1/2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
AGT103-TPhase 1Gene therapy / editingHIV proviral reservoir / autologous T cellsWeak signalFeatured results are safety only in this race
AinuovirinePhase 1Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
AV000103A (ICVAX)Phase 1VaccineHIV antigensWeak signalFeatured results are safety only in this race
BNT168Phase 1VaccineHIV antigensnot yet gradedNo reviewed efficacy summary in this indication
BNT351Phase 1Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
CPT31Phase 1PeptideHIV gp41Weak signalFeatured results are safety only in this race
MGD014Phase 1Multispecific antibodyHIV envelope gp120 x CD3Weak signalFeatured results are safety only in this race
MGD020Phase 1Multispecific antibodyHIV envelope gp41 x CD3Weak signalFeatured results are safety only in this race
MK-4646Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
UVAX-1107Phase 1VaccineHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
Fosamprenavir (Lexiva / Telzir)DiscontinuedSmall moleculeHIV proteasePartial signal
NCT00450580: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks (Week 48): FPV/RTV 1400/100 mg Once Daily (QD) + ABC/3TC FDC 600/300 mg Q — HIV-1 RNA <400 copies/mL: 81%; HIV-1 RNA >=400 copies/mL: 19% | FPV/RTV 700/100 mg BID + ABC/3TC FDC 600/300 mg QD — HIV-1 RNA <400 copies/mL: 82%; HIV-1 RNA >=400 copies/mL: 18%
NCT00363142: Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24 (Week 24): FPV/r100 92.1% | FPV/r200 94.2%

Large race: only the 63 furthest-along competitors are listed; 5 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Prezista (Darunavir) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 4HIVRecruiting
Est. primary completion 2027-06 · NCT06337032 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 3HIVNot yet recruiting
Est. primary completion 2029-06 · NCT07792096 · CT.gov ↗
What to watch

See the full readout calendar ↗